Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of South Florida Identifier:
First received: April 10, 2009
Last updated: August 9, 2013
Last verified: August 2013

RATIONALE: Losartan may be effective in treating patients with idiopathic pulmonary fibrosis.

PURPOSE: This clinical trial is studying the side effects of losartan and to see how well it works in treating patients with idiopathic pulmonary fibrosis.

Condition Intervention
Precancerous Condition
Drug: losartan

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Treatment of Idiopathic Pulmonary Fibrosis With Losartan: A Pilot Project

Resource links provided by NLM:

Further study details as provided by University of South Florida:

Primary Outcome Measures:
  • Stable or Improved Forced Vital Capacity (FVC) Response at 1 Year [ Time Frame: 1 year ] [ Designated as safety issue: No ]

    Forced vital capacity (FVC) must be >= 50% at baseline. Stable FVC response is defined as a -5% change in FVC from baseline up to a +5% change from baseline.

    Improved FVC response is defined as 5% or greater increase in the predicted value of FVC on pulmonary function testing following 12 months of treatment.

Secondary Outcome Measures:
  • Diffusion Capacity of Carbon Monoxide (DLCO) [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Total Lung Capacity by Plethysmography [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Baseline/Transition Dyspnea Index [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • 6-minute Walk Test Results [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Enrollment: 20
Study Start Date: March 2009
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Losartan
50 mg tablets of losartan taken daily by mouth for 1 year
Drug: losartan
50 mg losartan taken daily by mouth in capsule form for 1 year
Other Name: losartan potassium

Detailed Description:


  • Evaluate the effects of losartan potassium on disease progression in patients with idiopathic pulmonary fibrosis.
  • Determine the safety of this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral losartan potassium daily for 1 year in the absence of disease progression or unacceptable toxicity.

Patients undergo pulmonary function tests with gas diffusion lung volumes, Carbon monoxide diffusing capacity (DLCO) tests, and 6-minute walk tests at baseline and then at 3, 6, 9, and 12 months. Patients also complete baseline/transition dyspnea index questionnaires at baseline and then at 1, 3, 6, 9, and 12 months.


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Age > 21 years
  • Diagnosis of idiopathic pulmonary fibrosis
  • Patients taking Coumadin and/or N-acetylcysteine may participate in the study
  • Baseline forced vital capacity (FVC) must be greater than or equal to 50%
  • Baseline 6 minute walk test distance walked must be greater than or equal to 200 meters not requiring greater than 6 lpm of oxygen


  • Pregnant, intending to become pregnant or breastfeeding
  • Current or previous smoker of cigarettes or marijuana that recently quit within the last 6 months prior to enrollment
  • Allergy or allergic reaction to Losartan or any other angiotensin II receptor blocker
  • Taking losartan or any other angiotensin II receptor blocker
  • Baseline systolic blood pressure < 100 mmHg
  • Currently taking or has taken immunosuppressant agents within the last month such as azathioprine, cyclophosphamide, colchicine and/or prednisone
  • History of lung transplant
  • History of kidney failure or liver disease
  • Inability to attend clinic visits
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00879879

United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45267
Sponsors and Collaborators
University of South Florida
National Cancer Institute (NCI)
Principal Investigator: Marisa Couluris, DO University of South Florida
  More Information

Responsible Party: University of South Florida Identifier: NCT00879879     History of Changes
Other Study ID Numbers: SCUSF 0108 Pilot  SCUSF-PILOT-0108  5U10CA081920 
Study First Received: April 10, 2009
Results First Received: August 9, 2013
Last Updated: August 9, 2013
Health Authority: United States: Data and Safety Monitoring Board
United States: Federal Government
United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by University of South Florida:
precancerous condition

Additional relevant MeSH terms:
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Precancerous Conditions
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Lung Diseases, Interstitial
Anti-Arrhythmia Agents
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action processed this record on October 21, 2016